Pre-clinical stage company developing bispecific antibodies against pathogenic autoantibody generating B cells, to treat autoimmune disease broadly.
Biograph 55
Immunology
Total Addressable Market
Red Tree Board Member(s)
Red Tree Board Members
Jeremy Caldwell, Ph.D. (board chairman)
Jennifer Cochran, Ph.D.
Red Tree Participation
Led Series A